Eduardo Huarte

Eduardo Huarte

Auto-generated profile, based on publicly available information

Eduardo Huarte

Incyte Research Institute, 1801 Augustine Cut-off, Wilmington, DE19803, USA

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2006 in Cancer Research
Verified
Journal Article
Closed access
PDF file
ITIñigo Tirapu
Iñigo Tirapu
EHEduardo Huarte
Eduardo Huarte
CGCristiana Guiducci
Cristiana Guiducci
AAAinhoa Arina
Ainhoa Arina
MZMikel Zaratiegui
Mikel Zaratiegui
IMIGNACIO MELERO
IGNACIO MELERO
Artificially enforced expression of CD80 (B7-1) and CD86 (B7-2) on tumor cells renders them more immunogenic by triggering the CD28 receptor on T cells. The enigma is that such B7s interact with much higher affinity with CTLA-4 (CD152), an inhibitory receptor expressed by activated T cells. We show that unmutated CD80 is spontaneously expressed at low levels by mouse colon carcinoma cell lines and other transplantable tumor cell lines of various tissue origins. Silencing of CD80 by interfering RNA led to loss of tumorigenicity of CT26 colon carcinoma in immunocompetent mice, but not in immunodeficient Rag−/− mice. CT26 tumor cells bind CTLA-4Ig, but much more faintly with a similar CD28Ig chimeric protein, thus providing an explanation for the dominant inhibitory effects on tumor immunity displayed by CD80 at that expression level. Interestingly, CD80-negative tumor cell lines such as MC38 colon carcinoma and B16 melanoma express CD80 at dim levels during in vivo growth in syngeneic mice. Therefore, low CD80 surface expression seems to give an advantage to cancer cells against the immune system. Our findings are similar with the inhibitory role described for the dim CD80 expression on immature dendritic cells, providing an explanation for the low levels of CD80 expression described in various human malignancies. (Cancer Res 2006; 66(4): 2442-50)

14 September 2008 in Cancer Research
Verified
Journal Article
Open access
PDF file
EHEduardo Huarte
Eduardo Huarte
JCJuan R. Cubillos-Ruiz
Juan R. Cubillos-Ruiz
YNYolanda C. Nesbeth
Yolanda C. Nesbeth
USUciane K. Scarlett
Uciane K. Scarlett
DMDiana G. Martinez
Diana G. Martinez
JCJose R Conejo-Garcia
Jose R Conejo-Garcia
Dendritic cells (DC) and cytokines that expand myeloid progenitors are widely used to treat cancer. Here, we show that CD11c+DEC205+ DCs coexpressing α-smooth muscle actin and VE-cadherin home to perivascular areas in the ovarian cancer microenvironment and are required for the maintenance of tumor vasculature. Consequently, depletion of DCs in mice bearing established ovarian cancer by targeting different specific markers significantly delays tumor growth and enhances the effect of standard chemotherapies. Tumor growth restriction was associated with vascular apoptosis after DC ablation followed by necrosis, which triggered an antitumor immunogenic boost. Our findings provide a mechanistic rationale for selectively eliminating tumor-associated leukocytes to promote antitumor immunity while impeding tumor vascularization and to develop more effective DC vaccines based on a better understanding of the tumor microenvironment. [Cancer Res 2008;68(18):7684–91]

30 March 2005 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
EFEsperanza Feijoó
Esperanza Feijoó
Carlos AlfaroCarlos Alfaro
Carlos Alfaro
GMGuillermo Mazzolini
Guillermo Mazzolini
PSPatricia Serra
Patricia Serra
IPIvan Penuelas
Ivan Penuelas
IMIGNACIO MELERO
IGNACIO MELERO

12 July 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JSJerod A. Skyberg
Jerod A. Skyberg
TTTheresa Thornburg
Theresa Thornburg
MRMaryClare Rollins
MaryClare Rollins
EHEduardo Huarte
Eduardo Huarte
MJMark A. Jutila
Mark A. Jutila
DPDavid W. Pascual
David W. Pascual
γδ T cells have been postulated to act as a first line of defense against infectious agents, particularly intracellular pathogens, representing an important link between the innate and adaptive immune responses. Human γδ T cells expand in the blood of brucellosis patients and are active against Brucella in vitro. However, the role of γδ T cells in vivo during experimental brucellosis has not been studied. Here we report TCRδ−/− mice are more susceptible to B. abortus infection than C57BL/6 mice at one week post-infection as measured by splenic colonization and splenomegaly. An increase in TCRγδ cells was observed in the spleens of B. abortus-infected C57BL/6 mice, which peaked at two weeks post-infection and occurred concomitantly with diminished brucellae. γδ T cells were the major source of IL-17 following infection and also produced IFN-γ. Depletion of γδ T cells from C57BL/6, IL-17Rα−/−, and GMCSF−/− mice enhanced susceptibility to B. abortus infection although this susceptibility was unaltered in the mutant mice; however, when γδ T cells were depleted from IFN-γ−/− mice, enhanced susceptibility was observed. Neutralization of γδ T cells in the absence of TNF-α did not further impair immunity. In the absence of TNF-α or γδ T cells, B. abortus-infected mice showed enhanced IFN-γ, suggesting that they augmented production to compensate for the loss of γδ T cells and/or TNF-α. While the protective role of γδ T cells was TNF-α-dependent, γδ T cells were not the major source of TNF-α and activation of γδ T cells following B. abortus infection was TNF-α-independent. Additionally, bovine TCRγδ cells were found to respond rapidly to B. abortus infection upon co-culture with autologous macrophages and could impair the intramacrophage replication of B. abortus via IFN-γ. Collectively, these results demonstrate γδ T cells are important for early protection to B. abortus infections.

21 June 2011 in Journal of Leukocyte Biology
Verified
Journal Article
Open access
PDF file
JSJerod A Skyberg
Jerod A Skyberg
ARAmy Robison
Amy Robison
SGSarah Golden
Sarah Golden
MRMaryClare F. Rollins
MaryClare F. Rollins
GCGayle Callis
Gayle Callis
DPDavid W. Pascual
David W. Pascual
Human IBD, including UC and Crohn's disease, is characterized by a chronic, relapsing, and remitting condition that exhibits various features of immunological inflammation and affects at least one/1000 people in Western countries. Polyphenol extracts from a variety of plants have been shown to have immunomodulatory and anti-inflammatory effects. In this study, treatment with APP was investigated to ameliorate chemically induced colitis. Oral but not peritoneal administration of APP during colitis induction significantly protected C57BL/6 mice against disease, as evidenced by the lack of weight loss, colonic inflammation, and shortening of the colon. APP administration dampened the mRNA expression of IL-1β, TNF-α, IL-6, IL-17, IL-22, CXCL9, CXCL10, CXCL11, and IFN-γ in the colons of mice with colitis. APP-mediated protection requires T cells, as protection was abated in Rag-1−/− or TCRα−/− mice but not in IL-10−/−, IRF-1−/−, μMT, or TCRδ−/− mice. Administration of APP during colitis to TCRα−/− mice actually enhanced proinflammatory cytokine expression, further demonstrating a requirement for TCRαβ cells in APP-mediated protection. APP treatment also inhibited CXCR3 expression by TCRαβ cells, but not B or NK cells, in the colons of mice with colitis; however, depletion of CD4+ or CD8+ T cells alone did not abolish APP-mediated protection. Collectively, these results show that oral administration of APP protects against experimental colitis and diminishes proinflammatory cytokine expression via T cells.

1 March 2000 in Human Immunology
Verified
Journal Article
Closed access
FBFrancisco Borrás-Cuesta
Francisco Borrás-Cuesta
JGJosé-Javier Golvano
José-Javier Golvano
MGMarta Garcı́a-Granero
Marta Garcı́a-Granero
PSPablo Sarobe
Pablo Sarobe
JRJosé-Ignacio Riezu-Boj
José-Ignacio Riezu-Boj
JLJuan José Lasarte
Juan José Lasarte